Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelines

Patrick A. Brown; Matthew Wieduwilt; Aaron Logan; Daniel J. DeAngelo; Eunice S. Wang; Amir Fathi; Ryan D. Cassaday; Mark Litzow; Anjali Advani; Patricia Aoun; Bhavana Bhatnagar; Michael W. Boyer; Teresa Bryan; Patrick W. Burke; Peter F. Coccia; Steven E. Coutre; Nitin Jain; Suzanne Kirby; Arthur Liu; Stephanie Massaro; Ryan J. Mattison; Olalekan Oluwole; Nikolaos Papadantonakis; Jae Park; Jeffrey E. Rubnitz; Geoffrey L. Uy; Kristina M. Gregory; Ndiya Ogba; Bijal Shah

doi:10.6004/jnccn.2019.0024

Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelines

Patrick A. Brown, Matthew Wieduwilt, Aaron Logan, Daniel J. DeAngelo, Eunice S. Wang, Amir Fathi, Ryan D. Cassaday, Mark Litzow, Anjali Advani, Patricia Aoun, Bhavana Bhatnagar, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Peter F. Coccia, Steven E. Coutre, Nitin Jain, Suzanne Kirby, Arthur Liu, Stephanie MassaroRyan J. Mattison, Olalekan Oluwole, Nikolaos Papadantonakis, Jae Park, Jeffrey E. Rubnitz, Geoffrey L. Uy, Kristina M. Gregory, Ndiya Ogba, Bijal Shah

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.

Original language	English
Pages (from-to)	414-423
Number of pages	10
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	17
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2019.0024
State	Published - 2019

Access to Document

10.6004/jnccn.2019.0024

Cite this

Brown, P. A., Wieduwilt, M., Logan, A., DeAngelo, D. J., Wang, E. S., Fathi, A., Cassaday, R. D., Litzow, M., Advani, A., Aoun, P., Bhatnagar, B., Boyer, M. W., Bryan, T., Burke, P. W., Coccia, P. F., Coutre, S. E., Jain, N., Kirby, S., Liu, A., ... Shah, B. (2019). Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 17(5), 414-423. https://doi.org/10.6004/jnccn.2019.0024

@article{ea6e3d3cdc784de6bce1c46b4bd7fb09,

title = "Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelines",

abstract = "Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.",

author = "Brown, {Patrick A.} and Matthew Wieduwilt and Aaron Logan and DeAngelo, {Daniel J.} and Wang, {Eunice S.} and Amir Fathi and Cassaday, {Ryan D.} and Mark Litzow and Anjali Advani and Patricia Aoun and Bhavana Bhatnagar and Boyer, {Michael W.} and Teresa Bryan and Burke, {Patrick W.} and Coccia, {Peter F.} and Coutre, {Steven E.} and Nitin Jain and Suzanne Kirby and Arthur Liu and Stephanie Massaro and Mattison, {Ryan J.} and Olalekan Oluwole and Nikolaos Papadantonakis and Jae Park and Rubnitz, {Jeffrey E.} and Uy, {Geoffrey L.} and Gregory, {Kristina M.} and Ndiya Ogba and Bijal Shah",

note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2019.",

year = "2019",

doi = "10.6004/jnccn.2019.0024",

language = "English",

volume = "17",

pages = "414--423",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "5",

}

Brown, PA, Wieduwilt, M, Logan, A, DeAngelo, DJ, Wang, ES, Fathi, A, Cassaday, RD, Litzow, M, Advani, A, Aoun, P, Bhatnagar, B, Boyer, MW, Bryan, T, Burke, PW, Coccia, PF, Coutre, SE, Jain, N, Kirby, S, Liu, A, Massaro, S, Mattison, RJ, Oluwole, O, Papadantonakis, N, Park, J, Rubnitz, JE, Uy, GL, Gregory, KM, Ogba, N & Shah, B 2019, 'Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 5, pp. 414-423. https://doi.org/10.6004/jnccn.2019.0024

TY - JOUR

T1 - Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelines

AU - Brown, Patrick A.

AU - Wieduwilt, Matthew

AU - Logan, Aaron

AU - DeAngelo, Daniel J.

AU - Wang, Eunice S.

AU - Fathi, Amir

AU - Cassaday, Ryan D.

AU - Litzow, Mark

AU - Advani, Anjali

AU - Aoun, Patricia

AU - Bhatnagar, Bhavana

AU - Boyer, Michael W.

AU - Bryan, Teresa

AU - Burke, Patrick W.

AU - Coccia, Peter F.

AU - Coutre, Steven E.

AU - Jain, Nitin

AU - Kirby, Suzanne

AU - Liu, Arthur

AU - Massaro, Stephanie

AU - Mattison, Ryan J.

AU - Oluwole, Olalekan

AU - Papadantonakis, Nikolaos

AU - Park, Jae

AU - Rubnitz, Jeffrey E.

AU - Uy, Geoffrey L.

AU - Gregory, Kristina M.

AU - Ogba, Ndiya

AU - Shah, Bijal

PY - 2019

Y1 - 2019

N2 - Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.

AB - Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.

UR - http://www.scopus.com/inward/record.url?scp=85066289260&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0024

DO - 10.6004/jnccn.2019.0024

M3 - Article

C2 - 31085755

AN - SCOPUS:85066289260

SN - 1540-1405

VL - 17

SP - 414

EP - 423

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Acute lymphoblastic leukemia, version 1.2019 featured updates to the NCCN guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this